This may affect your ability to complete your registration.
SCHOOL OF MEDICINE - SoMCC
INDUSTRY INSIGHTS WITH MUSTANG VENTURES:
“China and the Valley of Death: Can China Help the Pharma Industry Change Course?”
Wednesday, May 8, 12:00-1:30pm
School of Medicine, Alway M106
Lunch will be served.
Charles Hsu, PhD, Senior Advisor, Mustang Ventures
School of Medicine Career Center
Overview: The Valley of Death has become a watchword in life sciences circles, as venture funding for discovery and translational development dries up and biotech companies starve. Meanwhile, the mainstream pharmaceutical industry has shed hundreds of thousands of jobs over the past decade, with no relief in sight. A trillion dollars worth of mergers have not preserved value but have instead appeared to accelerate value destruction. Few, if any, biotech or pharma analysts disagree with the notion of an industry in crisis. Meanwhile, China has created thousands of jobs in pharmaceutical R&D, not all of them at the expense of US jobs. Dozens of companies are growing, attracting significant venture financing. The Chinese government has committed over $500 billion to supporting the development of modern medicine in China. The Chinese pharma market is #3 in the world, growing at more than 25% per annum, and is forecast to overtake Japan in 2015 and the US perhaps ten years after that. Can the pharmaceutical and biotechnology industries use the emergence of China to re-invigorate themselves? If so, what do they need to do? Where are the opportunities and where are the risks?
About the Speaker: Dr. Hsu has over 28 years of life science industry experience, including 23 years as an investor and entrepreneur focused on life science and healthcare ventures. Prior to joining Mustang in 2011, he was a Venture Partner with Bay City Capital, and prior to that, a general partner of the Walden Group and its affiliate Walden International (from 1996 through 2003). He has co-founded and/or invested in almost 30 companies, including Alpha Beta, AutoImmune, DNX, Axys Pharmaceuticals, KOSAN, Urocor, Lexicon Genetics, Telik, Biomatrix, RPI (later SiRNA) and Aviron, Inc., all of which went public on NASDAQ. Aviron is best known for development of the Flumist nasal influenza vaccine which is now a key element of the global vaccine campaign against influenza.
Dr. Hsu has worked internationally throughout his career. Some of his non-US involvements include include Orgenics and D-Pharm (TASE: DPRM) in Israel; and Asia Renal Care, Mindray International (NYSE: MR), Eureka Pharmaceuticals, GenturaDx, LEAD Therapeutics, China Biologic and Wuxi Pharmatech (all in Greater China). He was co-founder and initial CEO of LEAD (successfully sold to BioMarin in 2010). He was an advisor on certain financing and corporate development events at Wuxi Pharmatech. He currently holds independent Board seats with a number of privately held life sciences companies, most of them operating in China.
Dr. Hsu is a frequently invited speaker and published author on various topics related to life sciences investing. He serves on the Board of the Jacobs University (Bremen, Germany) Foundation. He is an advisor to the Chinese American Biopharmaceutical Society (CABS) and ChinaBio LLC, and is a member of BayHelix. He holds an AB (Magna Cum Laude) in Biochemistry from Harvard and his PhD (Genetics) and MBA degrees from Stanford.
Questions? Email Carla Vaccarezza at email@example.com.